ASCO 2022 | Overcoming barriers in treating melanoma brain metastases
Bently Doonan
• 7 Jun 2022
Brain metastases remain a major hurdle in optimizing patient outcomes in melanoma and current checkpoint inhibitors such as ipilimumab and nivolumab as well as targeted therapies have limited efficacy in the brain. Bently Doonan, MD, University of Florida, Gainesville, FL, discusses strategies to target melanoma brain metastases. Treating brain metastases remain an unmet need, where they can materialize even during melanoma treatment. Whilst surgery and stereotactic radiotherapy are options, novel treatment strategies are required. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
